References
- Stadler K, Masignani V, Eickmann M, et al. SARS-beginning to understand a new virus. Nat Rev Microbiol 2003;1:209–18.
- Kumar V, Tan KP, Wang YM, et al. Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors. Bioorg Med Chem 2016;24:3035–42.
- Chan JF, Lau SK, To KK, et al. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev 2015;28:465–522.
- Durai P, Batool M, Shah M, Choi S. Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control. Exp Mol Med 2015;47:e181.
- Holmes KV. SARS coronavirus: a new challenge for prevention and therapy. J Clin Invest 2003;111:1605–9.
- Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003;300:1763–7.
- Ryu HW, Lee BW, Curtis-Long MJ, et al. Polyphenols from Broussonetia papyrifera displaying potent alpha-glucosidase inhibition. J Agric Food Chem 2010;58:202–8.
- Fernandes B, Sagman U, Auger M, et al. β1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res 1991;51:718–23.
- van de Laar FA, Lucassen PL, Akkermans RP, et al. α-Glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005;28:154–63.
- Chang J, Warren TK, Zhao X, et al. Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses. Antiviral Res 2013;98:432–40.
- Papandreou MJ, Barbouche R, Guieu R, et al. The alpha-glucosidase inhibitor 1-deoxynojirimycin blocks human immunodeficiency virus envelope glycoprotein-mediated membrane fusion at the CXCR4 binding step. Mol Pharmacol 2002;61:186–93.
- Whitby K, Pierson TC, Geiss B, et al. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J Virol 2005;79:8698–706.
- Ryu HW, Lee JH, Kang JE, et al. Inhibition of xanthine oxidase by phenolic phytochemicals from Broussonetia papyrifera. J Korean Soc Appl Biol Chem 2012;55:587–94.
- Chen L, Li J, Luo C, et al. Binding interaction of quercetin-3-β-galactoside and its synthetic derivatives with SARS-CoV 3CLpro: structure-activity relationship studies reveal salient pharmacophore features. Bioorg Med Chem 2006;14:8295–306.
- Park JY, Jeong HJ, Kim JH, et al. Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe acute respiratory syndrome coronavirus. Biol Pharm Bull 2012;35:2036–42.
- Park JY, Kim JH, Kim YM, et al. Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases. Bioorg Med Chem 2012;20:5928–35.
- Park JY, Ko JA, Kim DW, et al. Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV. J Enzyme Inhib Med Chem 2016;31:23–30.
- Park JY, Kim JH, Kwon JM, et al. Dieckol, a SARS-CoV 3CL(pro) inhibitor, isolated from the edible brown algae Ecklonia cava. Bioorg Med Chem 2013;21:3730–7.
- Burnham KP, Anderson DR. Multimodel inference: understanding AIC and BIC in model selection. Sociol Methods Res 2004;33:261–304.
- Chou CY, Chien CH, Han YS, et al. Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus. Biochem Pharmacol 2008;75:1601–9.
- Ratia K, Pegan S, Takayama J, et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci USA 2008;105:16119–24.
- Nguyen B, Tanious FA, Wilson WD. Biosensor-surface plasmon resonance: quantitative analysis of small molecule-nucleic acid interactions. Methods 2007;42:150–61.